Skip to content

Clinical trials

Irritable Bowel Syndrome trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Irritable Bowel Syndrome Phase: Not applicable Country / region: United States Clear all

120 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20031
20051
20061
20072
20084
20097
20104
20112
20123
20132
20146
20153
20165
20178
20186
20199
20208
20219
20227
202310
20242
20259
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed84
Recruiting13
Terminated9
Unknown status6
Not yet recruiting5
Withdrawn2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of California, Los Angeles8
University of Michigan7
Baylor College of Medicine6
Beth Israel Deaconess Medical Center5
Massachusetts General Hospital4
Mayo Clinic3
Stanford University3
University of North Carolina, Chapel Hill3
Yale University3
Medical College of Wisconsin2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Irritable Bowel Syndrome120
Abdominal Pain22
Gastrointestinal Diseases8
Anxiety Disorders7
Fibromyalgia6
Pain6
Chronic Pain5
Diarrhea4
Digestive System Diseases4
Dyspepsia4

Trials

Showing 1 to 25 of 120. Each trial links to its page on Pharma Observatory.

20 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.